Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a new biotech company focused on cell depletion of pathologic cells in autoimmune and inflammatory disorders. Celexor has been formed based on Inmagene's IMG-018, a pDC depleting antibody targeting immunoglobulin-like transcript 7 (ILT7). Celexor will obtain the exclusive global rights to develop, manufacture, and commercialize IMG-018, which will be renamed CLXR-901, in a transaction anticipated to close later this month.
Inmagene Biopharmaceuticals has reported positive topline data from a Phase I study of IMG-004, being developed to potentially treat immunological diseases.
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals today announced data from a 16-week, global, Phase 2 clinical trial of izokibep in 135...